
Foghorn Therapeutics FHTX
$ 5.18
3.6%
Annual report 2025
added 03-11-2026
Foghorn Therapeutics P/CF Ratio 2011-2026 | FHTX
Annual P/CF Ratio Foghorn Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -4.13 | -2.49 | -2.47 | 1.13 | -16.9 | -7.06 | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.13 | -16.9 | -5.32 |
P/CF Ratio of other stocks in the Biotechnology industry
| Issuer | P/CF Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
-0.654 | - | 2.43 % | $ 254 M | ||
|
Grifols, S.A.
GRFS
|
14.1 | $ 7.72 | 1.85 % | $ 6.83 B | ||
|
Amphastar Pharmaceuticals
AMPH
|
8 | $ 19.68 | 0.92 % | $ 920 M | ||
|
Amarin Corporation plc
AMRN
|
862 | $ 14.5 | 0.03 % | $ 6.02 B | ||
|
GlaxoSmithKline plc
GSK
|
26 | $ 52.37 | 1.02 % | $ 173 B | ||
|
I-Mab
IMAB
|
-0.266 | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
11.6 | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
1.68 K | - | 2.54 % | $ 160 B | ||
|
Ascendis Pharma A/S
ASND
|
-17.6 | $ 221.59 | -0.13 % | $ 5 B | ||
|
Biophytis SA
BPTS
|
-23.1 | - | -13.47 % | $ 169 M | ||
|
Autolus Therapeutics plc
AUTL
|
-2.05 | $ 1.39 | 1.46 % | $ 355 M | ||
|
Midatech Pharma plc
MTP
|
-13.2 | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-3.88 | - | -1.52 % | $ 24.7 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-0.64 | - | - | $ 26.5 M | ||
|
ARCA biopharma
ABIO
|
-8.36 | - | 1052.0 % | $ 415 M | ||
|
Aeterna Zentaris
AEZS
|
-4.82 | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
-0.0018 | - | -10.17 % | $ 12.2 K | ||
|
Acorda Therapeutics
ACOR
|
-1.2 | - | -24.86 % | $ 820 K | ||
|
Albireo Pharma
ALBO
|
-5 | - | -0.23 % | $ 916 M | ||
|
Aileron Therapeutics
ALRN
|
-1.71 | - | 10.36 % | $ 9.8 M | ||
|
Acasti Pharma
ACST
|
-2.73 | - | 4.01 % | $ 150 M | ||
|
Институт стволовых клеток человека
ISKJ
|
-89 | - | - | - | ||
|
Heron Therapeutics
HRTX
|
-7.19 | $ 0.81 | 3.74 % | $ 135 M | ||
|
Avenue Therapeutics
ATXI
|
-0.0603 | - | -52.27 % | $ 4.45 M | ||
|
Adverum Biotechnologies
ADVM
|
-0.826 | - | - | $ 86.2 M | ||
|
Acer Therapeutics
ACER
|
-0.401 | - | 2.71 % | $ 14 M | ||
|
Advaxis
ADXS
|
-0.0633 | - | -9.65 % | $ 45.9 M | ||
|
Ayala Pharmaceuticals
AYLA
|
-0.224 | - | - | $ 7.46 M | ||
|
Benitec Biopharma
BNTC
|
-23.6 | $ 11.05 | 0.64 % | $ 455 M | ||
|
Atreca
BCEL
|
-0.607 | - | -11.76 % | $ 5.79 M | ||
|
BioDelivery Sciences International
BDSI
|
7.5 | - | -4.8 % | $ 255 M | ||
|
BeiGene, Ltd.
BGNE
|
-1.8 K | - | 0.49 % | $ 251 B | ||
|
Calithera Biosciences
CALA
|
-14.5 | - | -10.95 % | $ 876 K | ||
|
Cara Therapeutics
CARA
|
-0.588 | - | -3.03 % | $ 260 M | ||
|
ChemoCentryx
CCXI
|
-0.024 | - | - | $ 3.74 B | ||
|
Immunovant
IMVT
|
-6 | $ 24.1 | 4.85 % | $ 3.65 B | ||
|
Bellerophon Therapeutics
BLPH
|
-4.42 | - | -74.18 % | $ 955 K | ||
|
Incyte Corporation
INCY
|
13.8 | $ 90.36 | -0.47 % | $ 17.6 B | ||
|
InMed Pharmaceuticals
INM
|
-0.235 | $ 0.74 | -9.75 % | $ 1.81 M | ||
|
INmune Bio
INMB
|
-17.6 | $ 1.17 | -0.43 % | $ 21 M | ||
|
Checkpoint Therapeutics
CKPT
|
-5.15 | - | - | $ 169 M | ||
|
Clovis Oncology
CLVS
|
-1.18 | - | -7.23 % | $ 13 M | ||
|
Aeglea BioTherapeutics
AGLE
|
-4.6 | - | - | $ 1.01 B | ||
|
CureVac N.V.
CVAC
|
-4.82 | - | - | $ 867 M | ||
|
Compugen Ltd.
CGEN
|
6.2 | $ 2.13 | 1.91 % | $ 199 M | ||
|
Innate Pharma S.A.
IPHA
|
-6.2 | $ 1.35 | 15.38 % | $ 235 M | ||
|
Akero Therapeutics
AKRO
|
-14.1 | - | - | $ 3.67 B | ||
|
Arbutus Biopharma Corporation
ABUS
|
-5.18 | $ 4.43 | 4.6 % | $ 735 M | ||
|
Inventiva S.A.
IVA
|
-11.2 | $ 6.1 | 5.5 % | $ 138 M | ||
|
Akouos
AKUS
|
-2.7 | - | 0.23 % | $ 488 M |